Concord Biotech Limited receives EIR from USFDA for API facility at Dholka

Concord Biotech Limited has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for the inspection carried out by them at our API facility at Dholka from 28th April 2025 till 2nd May 2025.

The USFDA has officially concluded its inspection, which is now closed under 21 CFR 20.64(d)(3). This closure indicates that no regulatory action is required, and the facility is permitted to continue its operations without any restrictions.

Shares of Concord Biotech Limited was last trading in BSE at Rs. 1822.50 as compared to the previous close of Rs. 1840.05. The total number of shares traded during the day was 8061 in over 1181 trades.

The stock hit an intraday high of Rs. 1841.35 and intraday low of 1777.75. The net turnover during the day was Rs. 14627776.00.

Source : Equity Bulls

Keywords

ConcordBiotech Pharmaceuticals INE338H01029 EIR USFDA APIFacility Dholka